As part of the regulatory action, memantine/donepezil extended-release capsules have been granted a 180-day exclusivity in patients with Alzheimer disease, with Everolimus receiving approval for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback